Washington University researchers tracked more than 333,000 U.S. veterans with type 2 diabetes for three years and found cardiovascular benefits from GLP-1 drugs such as Ozempic, Wegovy, Mounjaro and Zepbound fade soon after treatment stops. Even six months off raised major event risk; after two yea